• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Certara’s Simcyp division awarded FDA modeling and simulation grant

Certara’s Simcyp division awarded FDA modeling and simulation grant

October 20, 2016
CenterWatch Staff

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, has announced that the Office of Generic Drugs (OGD), FDA has awarded it a multi-year research grant to create and validate a physiologically-based pharmacokinetic (PBPK) modeling and simulation framework that complements existing models within the Simcyp Population-based Simulator. The new models will predict and simulate the behavior of supersaturating orally-dosed drug products in the human gastro-intestinal (GI) tract. This platform will also permit new product performance to be assessed and compared to reference products.

“We are proud to be working with the FDA and the University of Leuven in Belgium on this important project. Together, we are leveraging the advances in regulatory science and computing power to find new ways to recognize the value provided by model-based drug development,” said Certara CEO Edmundo Muniz, M.D., Ph.D. “This new modeling framework will eventually be used to perform virtual bioequivalence studies and virtual assessments of food effects on the in vivo behavior of low solubility drugs, thus avoiding unnecessary clinical studies when the outcomes can be predicted accurately using the models.”

The Simcyp Simulator, which includes a sophisticated and well recognized oral absorption module—the Advanced Dissolution Absorption and Metabolism (ADAM) model—already includes fluid dynamics models and physiological fluids. It can simulate clinical trials and predict variability between individuals in different populations rather than just for an “average person.” The Simulator is complemented by the separate Simcyp In Vitro Data Analysis (SIVA) Toolkit considered essential for model validation and extracting appropriate parameters from in vitro experiments prior to performing in vivo simulations.

A very high proportion of new drug candidates are poorly soluble which can severely limit their bioavailability. In order to ameliorate this issue a widely used approach is to formulate to create supersaturated solutions of drug. However, supersaturated solutions carry with them a precipitation risk which can severely limit the intended benefits of this approach. Thus, the ability to anticipate these properties and react accordingly can be critical to the success of a drug development program. This new project aims to further develop state-of-the art mechanistic models and workflows to improve the prediction of the in vivo behavior of supersaturating drug products. The models should enable sponsors to employ appropriate formulation strategies and either prevent precipitation or mitigate its impact earlier than before.

Dr. David Turner, principal scientist at Simcyp and the principal investigator on the grant said, “Prediction of supersaturation and precipitation kinetics of drugs and drug products especially in the complex, variable GI luminal environment is a challenging task. However, with the advance of biomimetic in vitro experiments coupled to state-of-the art mathematical models of nucleation and crystal growth, the team will develop robust approaches to predict the oral absorption profiles of drugs from such products.”

“Simcyp will develop physiologically-based mechanistic supersaturation and precipitation models along with a supporting physiology and variability database,” said Professor Augustijns from the Drug Delivery and Disposition Unit in the Department of Pharmaceutical and Pharmacological Sciences at the University of Leuven. “My team performs in vitro and clinical studies with supersaturating formulations which are to be used to validate Simcyp’s models. We will validate the platform and database against clinical pharmacokinetic data on the available drug products.”

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing